Open Access

Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study

  • Ye-Jee Kim1,
  • Nam-Kyong Choi2, 3,
  • Mi-Sook Kim4,
  • Joongyub Lee2,
  • Yoosoo Chang5,
  • Jong-Mi Seong1,
  • Sun-Young Jung1,
  • Ju-Young Shin1,
  • Ji-Eun Park6, 7 and
  • Byung-Joo Park1, 4, 6Email author
Contributed equally
Diabetology & Metabolic Syndrome20157:8

DOI: 10.1186/s13098-015-0002-y

Received: 23 June 2014

Accepted: 22 January 2015

Published: 15 February 2015

Abstract

Background

Low-dose aspirin is recommended to reduce the risk of cardiovascular disease. However, the questions with regard to primary prevention have been raised among patients with diabetes. We evaluated low-dose aspirin use for preventing ischemic stroke in patients with diabetes using a national health insurance database.

Methods

Using data from the Korean Health Insurance Review and Assessment Service database from January 1, 2005, through December 31, 2009, a population-based retrospective cohort study was conducted with incident patients with diabetes aged 40 to 99 years old with the initial use of low-dose aspirin during the index period from January 1, 2006 to December 31, 2007. We matched each low-dose aspirin user to one non-user using a propensity score. The Cox proportional hazards model was used to compare the risk of hospitalization for ischemic stroke in users and nonusers of low-dose aspirin until December 31, 2009.

Results

Out of 261,065 incident patients with diabetes, 15,849 (6.2%) were low-dose aspirin users. Compared to non-users, the adjusted hazard ratio (95% confidence interval) of low-dose aspirin users for hospitalization due to ischemic stroke was 1.73 (95% CI; 1.41-2.12). In a sensitivity analysis of study subjects with more than 1 year follow-up periods, slightly higher adjusted hazard ratio (1.97, 95% CI; 1.51-2.62) was observed. In the subgroup analyses, there were no significant changes in the risk of hospitalization for ischemic stroke irrespective of gender, age, or comorbidity.

Conclusions

In this study of patients with diabetes, the use of low-dose aspirin showed an increased risk of hospitalization for ischemic stroke. These results suggest that low-dose aspirin use for the primary prevention of ischemic stroke should be reconsidered in patients with diabetes.

Keywords

Aspirin Diabetes mellitus Ischemic stroke Health insurance claims database Retrospective cohort study

Background

Low-dose aspirin is recommended to prevent cardiovascular morbidity and mortality in high risk patients with myocardial infarction or ischemic stroke for the purpose of secondary prevention. It is also recommended to prevent cardiovascular events in the adult general population without a previous history of cardiovascular disease [1].

However, the Primary Prevention Project (PPP) trial raised doubt about the effectiveness of aspirin in diabetes patients [2]. Two subsequent randomized controlled trials that enrolled only patients with diabetes did not show a benefit of low-dose aspirin in primary prevention for cardiovascular disease, but did report an increased risk of gastrointestinal bleeding [3,4]. A meta-analysis by the Antithrombotic Trialists’ Collaboration provided subgroup analyses including patients with diabetes and found that the effects of low-dose aspirin on major vascular events were not statistically significant [5]. Furthermore, another meta-analysis including diabetic patients without cardiovascular disease found no significant reduction in the risk of major cardiovascular events with low-dose aspirin [6]. However, the previous studies were not sufficient to identify the effect of primary prevention due to their small sample size, no information on the use of statins, low level of compliance to aspirin therapy, switching aspirin use status during follow-up, or lack of precision of outcome measures [2-4,6]. Based on the limited evidence available, recent guidelines for managing diabetes mellitus narrow down the target of low-dose aspirin use for primary prevention to include only men aged over 50 years and women aged over 60 years, with an additional risk factor [7]. However, questions have been constantly raised about the use of low-dose aspirin on primary prevention of cardiovascular disease among patients with diabetes. Well-designed real world studies could be help to provide evidence determining the treatment effect with assessing the impact of age, gender or comorbidity. We attempted to evaluate the risk of ischemic stroke preferentially, because incidence rate for ischemic stroke was greater than any other cardiovascular diseases among patients with diabetes [8]. The objectives of this study were to evaluate the preventive effects of low-dose aspirin for ischemic stroke among the incident patients with diabetes compared with non-users.

Methods

Ethical approval

This study was approved by the Institutional Review Board of the National Evidence-based Collaboration Agency (NECA IRB09-011-2).

Study design and data source

A retrospective cohort study design was used to evaluate low-dose aspirin use for preventing ischemic stroke in patients with diabetes.

This study was conducted using the Health Insurance Review and Assessment Service (HIRA) database. The HIRA database includes all information on approximately 50 million people, whole Korean population covered by the National Health Insurance (NHI) program since 2000. Every resident in South Korea is provided with a unique civil registration number. After with the NHI program provides coverage for all residents with the form of compulsory social insurance, which ensured the complete follow-up of study participants. We obtained claims data for patients that had been submitted by healthcare providers between January 1, 2005 and December 31, 2009 with anonymized identifiers given by HIRA to protect privacy, according to the Act on the Protection of Personal Information Maintained by Public Agencies. The database contains information on demographic records, diagnosis, procedures performed, and prescriptions. Demographic information included age, gender, and national health insurance type. The health insurance type was composed of two parts, health insurance based on employment or residential area and a separate program for the lower-income Medicaid group, which covered 3-5% of the whole population [9]. All diagnoses were coded using the Korean Classification of Disease, fifth edition (KCD-5) modification of the International Classification of Disease and Related Health Problems, 10th revision (ICD-10). Procedures were entered into the database based on the HIRA coding system. The prescription data included the brand name and generic name of the drug according to the HIRA drug formulary code, prescription date, and duration.

Study population and exposure measure

The study cohort consisted of incident diabetes patients during the index period (January 1, 2006 to December 31, 2007), at 40 to 99 years of age at cohort entry (Figure 1). A patient with diabetes was defined as a patient diagnosed with diabetes (ICD-10, E10-14) and who had received a prescription for anti-diabetic medication(s) (oral hypoglycemic agents or insulin) in the same claim during the index period from January 1, 2006 to December 31, 2007. Because diabetes itself was regarded as a major risk factor for cardiovascular disease, we included incident patients with diabetes. To identify incident patients with diabetes, study participants were excluded if they had any claims of diabetes during the one year (January 1, 2005 to December 31, 2005) preceding the start of the index period. The study population was classified as low-dose aspirin (75–162 mg/day) users or non-users. The use of low dose aspirin was identified from the claims during the index period. The index date was defined as the date of low-dose aspirin initiation in low-dose aspirin users, and randomly chosen date among physician visit dates during the index period in non-users [10].
Figure 1

Schematic description of the study period.

Patients were excluded from the study i) if they had a prescription of aspirin as an analgesic agent during the study period (January 1, 2005 to December 31, 2009), or ii) received low-dose aspirin before the index period, or iii) had already recorded ischemic heart disease (I20-25) or ischemic stroke (I63) or had been prescribed anti-thrombotic drugs (abcximab, argatroban, bemiparin, beraprost, cilostazol, clopidogrel, dalteparin, dipyridamole, enoxaparin, fondaparinux, heparin, iloprost, indobufen, lepirudin, limaprost, mesoglycan, nadroparin, ozagrel, reviparin, parnaparin, RH-tissue type plasminogen activator, sarpogrelate, streptokinase, sulodexide, sulfomucopolysaccharide, tirofiban, treprostinil, tenecteplase, ticlopidine, triflusal, urokinase, or warfarin; all the anti-thrombotic drugs covered by the HIRA during the study period) before the index period.

Study outcome

The study outcomes of interest were defined as the principal and subsidiary diagnosis of hospitalization for ischemic stroke (I63).

Follow-up

A patient was considered to be continuously exposed to low-dose aspirin if he or she filled a prescription within the end date of the previous prescription plus 1.5 times the prescription days’ supply [11]. Of the non-users, survival time was censored for those who initiated low-dose aspirin during the follow-up period (January 1, 2006 to December 31, 2009). All patients were followed until they experienced an ischemic stroke, initiation of aspirin in non-users, death, or until the end of the follow-up period (December 31, 2009), whichever came first. Date of death was identified by the ICD-10 codes (R96, R98, R99, and I46.1) that indicate patient death in the claims database.

Statistical analyses

Baseline characteristics were presented as numbers with percentages for categorical variables and as means with standard deviations for continuous variables. We analyzed the patient characteristics including gender, age, insurance type, diabetes-related factors, co-morbidities, and use of medications in the year before the index date. The insurance type was classified as health insurance, Medicaid, or switching between the two groups. Diabetes-related factors included the type of diabetes and whether oral hypoglycemic agents or insulin was being used to control the diabetes. We defined type 1 diabetes-only patients as those who were recorded as having the ICD-10 code E10, or else classified as type 2 diabetes patients. Comorbidities were identified by ICD-10 codes for each patient, including essential hypertension (I10), and dyslipidemia (E78). Potential confounding factors were the use of statins, angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), calcium channel blockers (CCB), beta blockers (BB), thiazide diuretics, and non-steroidal anti-inflammatory drugs (NSAIDs).

To reduce the effect of confounding by indication, we matched each low-dose aspirin user to one non-user on the basis of the propensity score, which was quantified as the likelihood of receiving low-dose aspirin in the year before the index date by multivariate logistic regression analysis [12]. In the model, the use of low-dose aspirin was used as a dependent variable, and all measured baseline patient characteristics as listed above were included in the analysis. We also tested the following clinically plausible interaction terms: age and co-morbidities, age and use of medications, as well as co-morbidities and use of medications. After calculating the predicted probabilities, we matched each low-dose aspirin user to one non-user using the Greedy 5-to-1 digit-matching algorithm [13]. Balances in the distribution of baseline covariates were estimated by the standardized difference between the two groups, before and after matching.

We performed a Cox proportional hazard analysis to evaluate the effects of low-dose aspirin on the incidence of ischemic stroke after adjusting for use of statins, ACEI, ARB, CCB, BB, thiazide diuretics, and NSAIDs during follow-up. The insurance type and anti-diabetic medications were adjusted since the unbalanced distribution was observed after propensity score matching. Hazard ratios and their 95% confidence intervals were calculated. The proportional hazard assumption was checked by examining the log-log plots of the hazard functions for each group. Subgroup analyses were conducted to explore the impact of each gender (male, female), age group (40–69, 70–99), type of diabetes (type 1 only, type2 and others), and presence of essential hypertension, dyslipidemia. To deal with confounding by indication, we also examined risk of hospitalization for ischemic stroke was associated with use of low-dose aspirin among study subjects with more than 1 year follow-up periods.

All statistical analysis was performed using SAS software (version 9.1, SAS Institute, Inc., Cary, NC, USA).

Results and discussion

From the HIRA database, 4,391,065 patients aged 40 to 99 years were diagnosed with diabetes between January 1, 2005 and December 31, 2009. Of these, we identified 569,950 incident patients with diabetes. After applying exclusion criteria, 261,065 patients were included in the initial cohort (6.2%) of whom were low-dose aspirin users and 93.8% of whom were aspirin non-users) and after matching by propensity score, 15,849 patients remained in each group (Figure 2).
Figure 2

Selection of the study participants from the Health Insurance Review and Sssessment Service database.

The baseline characteristics of the study population before and after matching are presented in Table 1. Before propensity score matching, the users and the non-users widely differed on a number of baseline characteristics. Among the initial cohort, the low-dose aspirin users were more likely to be older, to have essential hypertension (48.9% vs. 23.1%) and dyslipidemia (26.3% vs. 11.3%), and to use of medication: statins (26.5% vs. 11.7%), ACEI (13.8% vs. 4.9%), ARB (26.7% vs. 10.0%), CCB (39.0% vs. 19.3%), BB (16.7% vs. 10.8%), and thiazide diuretics (27.7% vs. 12.6%). However, propensity score matched groups were balanced for gender, age group, type of diabetes, diagnosis of essential hypertension and dyslipidemia, and use of medications considered. Standardized differences in patient characteristics, which were below 0.1 across the groups, demonstrate substantial improvement in the balance of covariates [14].
Table 1

Baseline characteristics of study cohort by use of low-dose aspirin before and after propensity score matching

Characteristic *

Initial cohort

Propensity score matched cohort

Aspirin non-user

Low-dose aspirin user

d

Aspirin non-user

Low-dose aspirin user

d

(N = 244,882)

(N = 16,183)

(N = 15,849)

(N = 15,849)

N

(%)

N

(%)

N

(%)

N

(%)

Gender

Male

144,933

(59.2)

9,192

(56.8)

0.0483

8,877

(56.0)

8,986

(56.7)

0.0139

Female

99,949

(40.8)

6,991

(43.2)

 

6,972

(44.0)

6,863

(43.3)

 

Age

40-49

73,569

(30.0)

3,806

(23.5)

0.3481

3,631

(22.9)

3,737

(23.6)

0.0158

50-59

76,267

(31.1)

5,165

(31.9)

0.0356

4,690

(29.6)

5,067

(32.0)

0.0516

60-69

57,709

(23.6)

4,433

(27.4)

0.1971

4,489

(28.3

4,342

(27.4)

0.0207

70-99

37,337

(15.2)

2,779

(17.2)

0.1385

3,039

(19.2)

2,703

(17.1)

0.0551

Insurance type

Health insurance

225,785

(92.2)

14,896

(92.0)

0.0212

14,032

(88.5)

14,615

(92.2)

0.1250

Medicaid

15,399

(6.3)

947

(5.9)

0.0779

1,334

(8.4)

920

(5.8)

0.1018

Switching

3,698

(1.5)

340

(2.1)

0.3086

483

(3.0)

314

(2.0)

0.0681

Type of diabetes

Type 1 only

10,505

(4.3)

910

(5.6)

0.0615

1,011

(6.4)

809

(5.1)

0.0548

 

Type 2 and others

234,377

(95.7)

15,273

(94.4)

 

14,838

(93.6)

15,040

(94.9)

 

Antidiabetic medication

OHA

206,194

(84.2)

14,315

(88.5)

0.1241

13,078

(82.5)

14,101

(89.0)

0.1854

OHA + insulin

38,688

(15.8)

1,868

(11.5)

 

2,771

(17.5)

1,748

(11.0)

 

Diagnosis of essential hypertension

Yes

56,688

(23.1)

7,912

(48.9)

0.5566

8,379

(52.9)

7,624

(48.1)

0.0954

Diagnosis of dyslipidemia

Yes

27,592

(11.3)

4,253

(26.3)

0.3918

4,601

(29.0)

4,072

(25.7)

0.0749

Medication use

Statins

28,601

(11.7)

4,283

(26.5)

0.3832

4,291

(27.1)

4,076

(25.7)

0.0308

 

ACEI

11,878

(4.9)

2,266

(13.8)

0.3102

2,194

(13.8)

2,028

(12.8)

0.0308

 

ARB

24,597

(10.0)

4,321

(26.7)

0.4404

4,301

(27.1)

4,063

(25.6)

0.0341

 

CCB

47,268

(19.3)

6,311

(39.0)

0.4439

6,552

(41.3

6,099

(38.5)

0.0584

 

Beta blockers

26,413

(10.8)

2,696

(16.7)

0.1713

3,291

(20.8)

2,624

(16.6)

0.1082

 

Thiazide diuretics

30,824

(12.6)

4,481

(27.7)

0.3834

4,811

(30.4)

4,264

(26.9)

0.0764

 

NSAID

145,733

(59.5)

10,155

(62.8)

0.0665

10,416

(65.7)

9,939

(62.7)

0.0628

d: standardized difference.

ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; NSAID: non-steroidal anti-inflammatory drugs; OHA: oral hypoglycemic agents SD: standard deviation.

*Baseline characteristics for study subjects were identified within one year before index date.

Standardized difference (d) of greater than 0.1 represents meaningful imbalance between study groups.

Table 2 shows the incidence rates and risk of ischemic stroke associated with the use of low-dose aspirin in the propensity score matched cohort. Of the low-dose aspirin users, 340 (2.15%) patients had an ischemic stroke compared with 158 (1.00%) in the matched aspirin non-users. The overall ischemic stroke rate was 5.4 per 1,000 person-years for aspirin users and 3.2 per 1,000 person-years for aspirin non-users. Using a Cox proportional hazards model, compared to aspirin non-users, the adjusted hazard ratio of aspirin users for hospitalization for ischemic stroke was 1.73 (95% confidence interval; 1.41-2.12).
Table 2

Incidence rates and risk of ischemic stroke associated with use of low-dose aspirin among patients with diabetes

  

Aspirin non-user

Low-dose aspirin user

 
  

Event (N)

Person-years

Crude incidence rate (/1,000 person-years)

Event (N)

Person-years

Crude incidence rate (/1,000person-years)

Crude hazard ratio (95%CI)

Adjusted hazard ratio * (95% CI)

Whole matched cohort

158

48,725

3.2

340

44,592

5.4

1.64 (1.32-1.98)

1.73 (1.41-2.12)

Gender

Male

81

27,565

2.9

137

25,224

5.4

1.86 (1.56-2.23)

1.93 (1.46-2.55)

 

Female

77

21,160

3.6

103

19,368

5.3

1.45 (1.08-1.95)

1.52 (1.13-2.15)

Age

40-69

85

39,758

2.1

136

37,060

3.7

1.69 (1.28-2.22)

1.81 (1.37-2.38)

 

70-99

73

8,967

8.1

104

7,867

11.6

1.65 (1.23-2.23)

1.72 (1.27-2.33)

Type of diabetes

Type 1 only

14

3,078

4.5

19

2,287

8.3

1.74 (0.87-3.47)

1.82 (0.90-3.68)

 

Type 2 and others

144

45,647

3.2

221

42,305

5.2

1.61 (1.31-1.99)

1.73 (1.40-2.14)

Diabetes with essential hypertension

Yes

97

24,791

3.9

135

21,306

6.3

1.59 (1.23-2.07)

1.69 (1.30-2.20)

No

61

23,934

2.5

105

23,286

4.5

1.70 (1.24-2.33)

1.81 (1.32-2.51)

Diabetes with dyslipidemia

Yes

39

13,501

2.9

48

11,255

4.3

1.44 (0.94-2.14)

1.68 (1.09-2.57)

No

119

35,224

3.4

192

33,337

5.8

1.65 (1.31-2.08)

1.75 (1.39-2.21)

CI: confidence interval.

*Adjusted Hazard Ratio calculated using Cox proportional hazard model adjusting for insurance type, anti-diabetic medications at baseline, use of statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics during follow-up.

We did not find any changes in risk related to gender, age group, and presence of hypertension, dyslipidemia from the results of subgroup analyses. Although point estimate for the risk was relatively low in female patients, the use of low-dose aspirin showed an increased risk of ischemic stroke in male patients (aHR 1.93, 95% CI; 1.46-2.55) or in female patients (aHR 1.52, 95% CI; 1.13-2.15). In the type of diabetes, type 1 only group was not statistically significant (aHR 1.82, 95% CI; 0.90-3.68). Use of aspirin increased the risk of hospitalization for an ischemic stroke regardless of the presence of comorbidities. The HRs for the patients with hypertension, without hypertension, with dyslipidemia, or without dyslipidemia were 1.69 (95% CI; 1.30-2.20), 1.81 (95% CI; 1.32-2.51), 1.68 (95% CI; 1.09-2.57), or 1.75 (95% CI; 1.39-2.21), respectively.

In a sensitivity analysis of study subjects with more than 1 year follow-up periods, we found slightly higher aHR (1.97, 95% CI; 1.51-2.62). The aHR for ischemic stroke was 3.25 (95% CI; 2.28-4.63) among males and 1.72 (95% CI; 1.16-2.57) among females. The association between the use of aspirin and the risk of hospitalization due to ischemic stroke maintained irrespective of gender, age, or comorbidities (Table 3).
Table 3

Sensitivity analysis for incidence rates and risk of ischemic stroke associated with use of low-dose aspirin among patients with diabetes who completed more than 1 year follow-up periods after index date

 

Aspirin non-user

Low-dose aspirin user

  
 

Event (N)

Person-years

Crude incidence rate (/1,000 person-years)

Event (N)

Person-years

Crude incidence rate (/1,000 person-years)

Crude Hazard Ratio (95% CI)

Adjusted Hazard Ratio * (95% CI)

Whole matched cohort

84

48,553

1.7

139

44,527

3.1

1.85 (1.41-2.44)

1.97 (1.51-2.62)

Gender

Male

42

27,476

1.5

78

25,182

3.1

3.01 (2.12-4.28)

3.25 (2.28-4.63)

 

Female

42

21,077

2.0

61

19,345

3.2

1.65 (1.65-2.45)

1.72 (1.16-2.57)

Age

40-69

48

39,633

1.2

85

37,019

2.3

1.98 (1.98-2.62)

2.12 (1.48-3.03)

 

70-99

36

8,921

4.0

54

7,508

7.2

1.79 (1.79-2.74)

1.89 (1.23-2.91)

Type of diabetes

Type 1 only

8

3,064

2.6

8

2,282

3.5

1.32 (0.50-3.52)

1.38 (0.50-3.77)

 

Type 2 and others

76

45,489

1.7

131

42,245

3.1

1.91 (1.44-2.54)

2.05 (1.54-2.74)

Diabetes with essential hypertension

Yes

48

24,669

1.9

82

21,272

3.9

2.03 (1.42-2.91)

2.14 (1.50-3.07)

No

36

23,885

1.5

57

23,225

2.5

1.67 (1.09-2.54)

1.78 (1.16-2.73)

Diabetes with dyslipidemia

Yes

24

13,444

1.8

27

11,240

2.4

1.34 (0.78-2.34)

1.60 (0.92-2.82)

No

60

35,109

1.7

112

33,287

3.4

2.04 (1.49-2.80)

2.13 (1.55-2.93)

CI: confidence interval.

*Adjusted Hazard Ratio calculated using Cox proportional hazard model adjusting for insurance type, anti-diabetic medications at baseline, use of statins, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers and thiazide diuretics during follow-up.

This retrospective cohort study showed that there was increased the risk of low-dose aspirin use for hospitalization due to ischemic stroke among incident diabetic patients without a prior history of cardiovascular diseases in a real-world setting. Moreover, we did not observe any differences in risk related to gender, age group, or presence of hypertension, or dyslipidemia in subgroup analyses and in a sensitivity analysis of study subjects with more than 1 year follow-up periods. These results suggest that the low-dose aspirin use for the primary prevention of ischemic stroke is unnecessary for patients with diabetes.

Contrary to our initial hypothesis, we found that use of low-dose aspirin increased the risk of hospitalization for ischemic stroke. Diabetes itself might be contributed to reduction of the effectiveness of aspirin due to accelerate platelet turnover [15-18]. Recently, De Berardis et al. reported that the use of aspirin was not associated with greater risk of major bleeding among patients with diabetes [19]. In this respect, the effect of aspirin in patients with diabetes was insufficient not only for preventing cardiovascular events but also for increasing the risk of bleeding. A higher dosing strategy has been proposed by some to overcome these changes in patients with diabetes based on the significant results of the Early Treatment of Diabetic Retinopathy Study trial (650 mg/day) [20]. Henry et al. suggested that repeated low-dose aspirin use daily instead of higher dosing strategy to improve clinical efficacy on patients with aspirin resistance [21]. We did not determine the effect of aspirin dosing due to restricting exposure to low-dose aspirin as current guidelines. Additional research is required to assess the effect of dose escalation for resolving aspirin resistance and the occurrence of adverse events in diabetic patients.

Our findings on the effects of ischemic stroke in diabetic patients correspond to the results of previous observational studies [22,23]. Leung et al. [22] conducted a longitudinal observational study to examine the benefit and harm of low-dose aspirin (75-325 mg/day) in Chinese type 2 diabetic patients. In a total of 5 731 patients, the use of aspirin was associated with increased risk of cardiovascular diseases and mortality in primary prevention (HR 2.07, 95% CI; 1.66-2.59) during the five-year follow-up. In addition, the study showed that the risk of gastrointestinal bleeding in aspirin users was rather high. A Swedish record linkage study [23] was performed to evaluate the effect of aspirin on mortality and serious bleeding in diabetic patients with and without cardiovascular diseases. During the maximum 18 months of follow-up, aspirin significantly increased mortality in the diabetic patients without cardiovascular disease. However, aspirin tended to decrease mortality among elderly diabetic patients with cardiovascular disease. Recently, Sacco et al. [24] performed prospective multicenter study, the use of low-dose aspirin was ineffective in primary prevention of major adverse cardiovascular events for patients with nephropathy (HR: 1.11 95% CI 0.91-1.35). On the other hand, the Fremantle Diabetes Study (FDS) [25] showed that regular aspirin use was independently associated with reduced cardiovascular disease mortality (HR 0.30, 95% CI; 0.09-0.95) and all-cause mortality (HR 0.53, 95% CI; 0.28-0.98) among the 651 low-dose aspirin users (7.7%) without prior cardiovascular disease. There was a possibility of selection bias in recruiting the FDS study participants: 1,426 were recruited to the cohort voluntarily among the postal code-defined urban community-dwellers with diabetes (2,258 patients). Previous studies provided explanations for the failure (non-responsiveness, resistance) of aspirin in the primary prevention of diabetic patients [15-18,22,23].

This study had several strengths. The study reflects the real world situation among a nationwide representative population, which covered all diabetic patients using the national health insurance claims database in Korea. For reducing bias due to confounding by indication, we restricted study subjects to those who were without any diagnosis or medications history of cardiovascular disease [26], and we applied advanced statistical methods like propensity score [12]. We identified potential confounding factors including pre-existing medical conditions and use of medication in the year prior to the index date. We included the insulin or oral hypoglycemic use as a proxy indicator for the severity of diabetes, and the presence of COPD as a proxy for the smoking. We also comprehensively considered widely used medications in relatively recent years such as statin and anti-hypertensives. The HIRA database is a valuable data source for epidemiologic research; the overall positive predictive value of the diagnosis was about 70% [27]. Diagnosis of severe condition such as ischemic stroke was reported to be higher accuracy for claims compared with those of other mild conditions [28]. In particular, diagnosis of diabetes (ICD-10 codes E10–14) in HIRA database was reported to have a positive predictive value of 72.3% in outpatients and 87.2% in inpatients compared to the clinical information obtained by using hospital medical records [29]. We considered both diagnosis and prescription to guarantee a more accurate definition of diabetic patients.

However, these results must be interpreted in light of some potential limitations. One is that despite applying advanced statistical methods like propensity score matching to reduce the effect of confounding, it could not completely rule out bias such as confounding by indications and unmeasured confounders. We could not consider variables that were not included in the claims database such as obesity, smoking, alcohol consumption, or use of over-the-counter drugs. Aspirin is available as an over-the-counter drug and prescription drug in South Korea. We assumed that most patients with diabetes received low-dose aspirin with a prescription during regular clinical visits for managing their diabetes because low-dose aspirin applied to health insurance coverage is discounted compared to over-the-counter self-medication. Accordingly, very few patients bought aspirin at the drug store as over-the-counter drug. We identified very low use of aspirin among the study subjects. Park IB et al. [30] also reported that significant underuse of aspirin therapy among the newly diagnosed diabetes in Korea previously.

Current guidelines for managing diabetes mellitus, aspirin is no longer recommended for CVD prevention at low CVD risk considering the balance of benefit and risk [31]. Based on our results, low-dose aspirin might be not effective with early-stage of diabetes. However, we did not follow-up those patients for a long time, therefore, this results should be interpreted with caution. Up to now, many retrospective studies have been published. On current evidence-conflicting stage, clinicians should evaluate the balance of benefit and risk of low-dose aspirin considering the prevalence period with diabetes. To confirm this issue, randomized controlled trial should be performed for generating strong evidence. Further studies of large-scale intervention trials [32,33] currently in progress will provide more confirmation of the role of low-dose aspirin for the primary prevention of cardiovascular diseases in patients with diabetes.

Conclusions

In summary, the use of low-dose aspirin was associated with the development of ischemic stroke in diabetic patients without cardiovascular diseases after restricting study subjects and propensity score matching. These results suggested that low-dose aspirin use for the primary prevention of ischemic stroke should be reconsidered in diabetic patients.

Notes

Abbreviations

ACEI: 

Angiotensin converting enzyme inhibitors

ARB: 

Angiotensin receptor blockers

BB: 

Beta blockers

CCB: 

Calcium channel blockers

CI: 

Confidence interval

HIRA: 

Health Insurance Review and Assessment Service

HR: 

Hazard ratio

ICD-10: 

International Classification of Disease and Related Health Problems, 10th Revision

NHI: 

National Health Insurance

NSAIDs: 

Non-steroidal anti-inflammatory drugs

PPP: 

Primary Prevention Project

Declarations

Acknowledgements

This study was supported by a grant from the National Evidence-based Healthcare Collaborating Agency in South Korea (NECA-A-11-002). We thank the Korean Health Insurance Review and Assessment Service for providing the insurance claims data.

Authors’ Affiliations

(1)
Korea Institute of Drug Safety and Risk Management
(2)
Medical Research Collaborating Center, Seoul National University College of Medicine/Seoul National University Hospital
(3)
Institute of Environmental Medicine, Seoul National University Medical Research Center
(4)
Department of Preventive Medicine, College of Medicine, Seoul National University
(5)
Center for Cohort Studies, Total Healthcare Screening Center, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine
(6)
National Evidence-based Healthcare Collaborating Agency
(7)
Department of Health Care Management and Policy, School of Public Health, National University

References

  1. Preventive US. Services Task Force: Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396–404.View ArticleGoogle Scholar
  2. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care. 2003;26(12):3264–72.View ArticlePubMedGoogle Scholar
  3. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Brit Med J. 2008;337:a1840.View ArticlePubMed CentralPubMedGoogle Scholar
  4. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–41.View ArticlePubMedGoogle Scholar
  5. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849–60.View ArticleGoogle Scholar
  6. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Brit Med J. 2009;339:b4531.View ArticlePubMed CentralPubMedGoogle Scholar
  7. American Diabetes Association. Standards of Medical Care in Diabetes-2012. Diabetes Care. 2012;35(1):S11–63.Google Scholar
  8. Kim J, Kim H, Kim H, Min JW, Park SW, Park IB, et al. Current status of the continuity of ambulatory diabetes care and its impact on health outcomes and medical cost in Korea using National Health Insurance database. J Korean Diabetes Assoc. 2006;30(5):377–87.View ArticleGoogle Scholar
  9. Kwon S. Thirty years of national health insurance in South Korea: lessons for achieving universal health care coverage. Health Policy Plan. 2009;24(1):63–71.View ArticlePubMedGoogle Scholar
  10. Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM. A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92(12):1447–51.View ArticlePubMedGoogle Scholar
  11. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449–57.PubMedGoogle Scholar
  12. D’Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–81.View ArticlePubMedGoogle Scholar
  13. Parson LS. Reducing bias in a propensity score matching techniques. In SAS SUGI 26, 2001:214–226. http://www2.sas.com/proceedings/sugi26/p214-26.pdf
  14. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27(12):2037–49.View ArticlePubMedGoogle Scholar
  15. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004;113:101–13.View ArticlePubMedGoogle Scholar
  16. Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res. 2007;119:517–24.View ArticlePubMedGoogle Scholar
  17. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia. 2008;51(3):385–90.View ArticlePubMedGoogle Scholar
  18. Pulcinelli FM, Biasucci LM, Riondino S, Giubilato S, Leo A, Di Renzo L, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30:1279–86.View ArticlePubMedGoogle Scholar
  19. De Berardis G, Lucisano G, D’Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes. JAMA. 2012;307(21):2286–94.View ArticlePubMedGoogle Scholar
  20. Investigators ETDRS. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA. 1992;268(10):1292–300.View ArticleGoogle Scholar
  21. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, et al. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemostasis. 2011;105(2):336–44.View ArticleGoogle Scholar
  22. Leung WY, So WY, Stewart D, Lui A, Tong PC, Ko GT, et al. Lack of benefits for prevention of cardiovascular disease with aspirin therapy in type 2 diabetic patients–a longitudinal observational study. Cardiovasc Diabetol. 2009;8:57.View ArticlePubMed CentralPubMedGoogle Scholar
  23. Welin L, Wilhelmsen L, Bjornberg A, Oden A. Aspirin increases mortality in diabetic patients without cardiovascular disease: a Swedish record linkage study. Pharmacoepidemiol Drug Saf. 2009;18(12):1143–9.View ArticlePubMedGoogle Scholar
  24. Sasso FC, Marfella R, Pagano A, Porta G, Signoriello G, Lascar N, et al. Lack of effect of aspirin in primary CV prevention in type 2 diabetic patients with nephropathy: results from 8 years follow-up of NID-2 study. Acta Diabetol 2014 Aug 11. [Epub ahead of print]Google Scholar
  25. Ong G, Davis TME, Davis WA. Aspirin Is Associated With Reduced Cardiovascular and All-Cause Mortality in Type 2 Diabetes in a Primary Prevention Setting - The Fremantle Diabetes Study. Diabetes Care. 2010;33(2):317–21.View ArticlePubMed CentralPubMedGoogle Scholar
  26. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA. 2010;304:897–8.View ArticlePubMedGoogle Scholar
  27. Park BJ, Sung JH, Park KD, Seo SW, Kim SW. Report of the evaluation for validity of discharged diagnoses in Korean Health Insurance database. Seoul: Seoul National University; 2003.Google Scholar
  28. Kim JY. Strategies to enhance the use of National Health Insurance Claims Database in generating health statistics. Seoul: Health Insurance Review and Assessment Services; 2005.Google Scholar
  29. Task Force Team for Basic Statistical Study of Korean Diabetes Mellitus of Korean Diabetes Association, Park IB, Kim J, Kim DJ, Chung CH, Oh JY, et al. Diabetes epidemics in Korea: reappraise nationwide survey of diabetes “diabetes in Korea 2007”. Diabetes Metab J. 2013;37(4):233–9.View ArticlePubMed CentralGoogle Scholar
  30. Park IB, Kim DJ, Kim J, Kim H, Kim H, Min KW, et al. Current status of aspirin user in Korean Diabetic Patients Using Korean Health Insurance Database. J Kor Diabetes Assoc. 2006;30(5):363–71.View ArticleGoogle Scholar
  31. American Diabetes Association. Standards of Medical Care in Diabetes-2015. 8. Cardiovascular Disease and Risk Management. Diabetes Care. 2015;38 Suppl 1:S49–57.View ArticleGoogle Scholar
  32. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, Tognoni G, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials. 2007;8:21.View ArticlePubMed CentralPubMedGoogle Scholar
  33. ASCEND Investigators. A Study of Cardiovascular Events iN Diabetes. Current Controlled Trials. 2005. http://clinicaltrials.gov/ct2/show/NCT00135226

Copyright

© Kim et al.; licensee BioMed Central. 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement